Recommendations on SARS-CoV-2 vaccination in adult patients with rheumatic diseases.
SARS-CoV-2
guideline
rheumatic diseases
vaccine
Journal
Rheumatology and immunology research
ISSN: 2719-4523
Titre abrégé: Rheumatol Immunol Res
Pays: Germany
ID NLM: 9918419176206676
Informations de publication
Date de publication:
01 Dec 2021
01 Dec 2021
Historique:
received:
10
11
2021
accepted:
11
11
2021
entrez:
30
6
2022
pubmed:
1
7
2022
medline:
1
7
2022
Statut:
epublish
Résumé
Vaccination against coronavirus disease 2019 (COVID-19) has been promoted all over the world and has become an important measure to control the pandemic. Patients with rheumatic diseases are at high risk of 2019-nCoV severe infection, hence are the target population with high priority for vaccination. In 2021, under the leadership of the Chinese Rheumatology Association, the recommendations on SARS-CoV-2 vaccination for adult patients with rheumatic diseases in China were proposed based on the current data, in combination with international guidelines and experts' opinions.
Identifiants
pubmed: 35772082
doi: 10.2478/rir-2021-0029
pii: rir-2021-0029
pmc: PMC9242139
doi:
Types de publication
Journal Article
Langues
eng
Pagination
213-216Informations de copyright
© 2021 Min Shen et al., published by Sciendo.
Déclaration de conflit d'intérêts
Conflict of Interest Xiaofeng Zeng is the Editor-in-Chief of the journal, and Mengtao Li and Yan Zhao are Associate Editors-in-Chief. The article was subject to the journal's standard procedures, with peer review handled independently of these members and their research groups.
Références
Ann Rheum Dis. 2020 Jan;79(1):39-52
pubmed: 31413005
Ann Rheum Dis. 2021 Apr;80(4):411-412
pubmed: 33563595
Arthritis Rheumatol. 2021 Oct;73(10):e60-e75
pubmed: 34346564
Ann Rheum Dis. 2021 Mar;80(3):384-391
pubmed: 33051220
Hamostaseologie. 2021 Jun;41(3):184-189
pubmed: 33822348